Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/139086LIQUID COMPOSITION COMPRISED OF A MICELLAR CASEIN CONCENTRATE
WO 02.07.2020
Int.Class A23L 33/19
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
17Amino acids, peptides or proteins
19Dairy proteins
Appl.No PCT/NL2019/050876 Applicant AUSNUTRIA B.V. Inventor ROMBOUTS, Wolf Harald
The present invention relates to a liquid composition comprised of a micellar casein concentrate (MCC), more specifically a MCC that is of non-bovine origin. The present invention further relates to food products comprised of the liquid composition of present invention and methods for the production of the liquid composition of present invention.
2.WO/2020/140112METHOD FOR STABILIZING BIOACTIVITY OF GROWTH FACTOR
WO 02.07.2020
Int.Class A61K 38/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin
Appl.No PCT/US2019/068910 Applicant EXCEL MED, LLC Inventor HUANG, Lynn, L.H.
This invention discloses a method for stabilizing bioactivity of a growth factor, including mixing collagen with a growth factor and freeze drying the mixture to remove water. After this treatment, the bioactivity of the growth factor at room temperature remains stable for at least 7 days.
3.WO/2020/136276DRY POWDER INHALATION FORMULATION AND ITS USE FOR THE THERAPEUTIC TREATMENT OF LUNGS
WO 02.07.2020
Int.Class A61K 38/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
28Insulins
Appl.No PCT/EP2019/087122 Applicant UNIVERSITÉ LIBRE DE BRUXELLES Inventor AMIGHI, Karim
Dry powder inhalation formulation comprising at least one API and a lipid matrix comprising at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and their mixture and its manufacturing method.
4.WO/2020/136666A LYOPHILIZED COMPOSITION OF PEGASPARGASE
WO 02.07.2020
Int.Class C12N 9/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
78acting on carbon to nitrogen bonds other than peptide bonds (3.5)
80acting on amide bonds in linear amides
82Asparaginase
Appl.No PCT/IN2019/050402 Applicant GENNOVA BIOPHARMACEUTICALS LIMITED Inventor MUKHERJEE, Tathagata
The present invention relates to a novel, economically viable, storage stable, lyophilized composition of pegaspargase. The composition comprises pegaspargase, a cryoprotectant, a bulking agent, a buffer and may optionally contain other pharmaceutically acceptable excipients including but not limited to a salt. The composition of the present invention is stable for extended periods over significant range of temperatures, without the presence of any significant amount of impurities. The present invention also relates to an economically viable and scalable lyophilization process for the production of the storage stable composition of pegaspargase.
5.WO/2020/136647LOADED NANOPARTICLES HAVING RNA UNLOCKING MECHANISM
WO 02.07.2020
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/IL2019/051407 Applicant YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. Inventor WILLNER, Itamar
Nanoparticle loaded with pharmaceutically active agent(s) being locked within said nanoparticle by an RNA unlocking mechanism, compositions comprising said nanoparticles and uses thereof in the treatment of diseases and disorders.
6.WO/2020/139300A COMBINATION COMPRISING GRANULOCYTE COLONY STIMULATING FACTOR
WO 02.07.2020
Int.Class A61K 38/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
Appl.No PCT/TR2019/051223 Applicant ARVEN ILAC SANAYI VE TICARET ANONIM SIRKETI Inventor TOKSOZ, Zafer
The present invention relates to a pharmaceutical combination comprising granulocyte-colony stimulating factor (G-CSF) and a biguanide compound for treating a patient with cancer with a targeted therapy in combination with chemotherapies.
7.WO/2020/139843ENGINEERED HEPATITIS B CORE POLYPEPTIDE
WO 02.07.2020
Int.Class C07K 1/113
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
107by chemical modification of precursor peptides
113without change of the primary structure
Appl.No PCT/US2019/068370 Applicant THE BOARD OF TRUSTEE OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor SWARTZ, James R.
Genetically modified HBc polypeptides are provided.
8.WO/2020/134563APPLICATION OF POLYPEPTIDE IN PREPARING FORMULATION FOR PREVENTING AND TREATING HUMAN PAPILLOMAVIRUS INFECTION
WO 02.07.2020
Int.Class A61K 38/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
Appl.No PCT/CN2019/114968 Applicant GENLOCI BIOTECHNOLOGIES INC., Inventor LING, Jianqun
The present invention discloses an application of a polypeptide in preparing formulation for preventing and treating human papillomavirus infection, simultaneously provides a polypeptide formulation for preventing and treating human papillomavirus infection, the polypeptide formulation is prepared by taking an effective dose of the polypeptide as an active ingredient, and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients.
9.WO/2020/133605ARTIFICIALLY SYNTHESIZED POLYPEPTIDE H-473 AND USE THEREOF
WO 02.07.2020
Int.Class C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
Appl.No PCT/CN2019/072013 Applicant CHINA WEST NORMAL UNIVERSITY Inventor HOU, Wanru
An artificially synthesized polypeptide H-473 and use thereof. Said polypeptide H-473 has an amino acid sequence of RGLRGLR, a molecular weight of 827 Da, and a PI of 12.30. Use of the polypeptide H-473 in preparation of anti-cancer medicaments, anti-senile dementia, ease of pain, etc. The polypeptide H-473 drug provides scientific bases and directions for the research and development of anti-cancer, anti-asthma, anti-senile dementia and pain relief, also provides a valuable resource for studying mechanisms of anti-cancer, anti-asthma, anti-senile dementia, ease of pain and anti-psoriasis, and provides new directions for researching novel means for anti-cancer, anti-asthma, anti-senile dementia, pain relief, anti-psoriasis and anti-age-related macular degeneration (AMD).
10.WO/2020/132789MUTATED HUMAN 2IG-B7-H3 PROTEIN CODING GENE, RECOMBINANT VECTOR, HOST CELL CONTAINING SAME, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
WO 02.07.2020
Int.Class C12N 15/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
Appl.No PCT/CN2018/123049 Applicant HUANG, Haidong Inventor HUANG, Haidong
The present invention relates to the field of genetic engineering, particularly to a mutated human 2Ig-B7-H3 protein coding gene, a protein, a recombinant vector, and a pharmaceutical composition containing the gene or protein. The regulatory expression, interaction and signal transmission of the protein encoded by the gene plays an important role in the process of tumor immune response, and provides an advantageous way to prevent and treat cancer.